
Pathology Perspectives on Clinical Genomics

Debra G.B. Leonard, MD, PhD, FCAP Weill Cornell Medical College May 3, 2012

Overview of Presentation

- IOM Report on Recommended Pathway for Omics Test Evaluation Framework
- College of American Pathologists Evaluation of Genomics
- Genomics from a Molecular Pathologist's Perspective








INSTITUTE OF MEDICINE Advising the nation/Improving health


OF THE NATIONAL ACADEMIES

Recommended Framework for Evaluation of Omics Tests from Discovery to Test Validation and Clinical Utility Assessment






Understanding of the Human Genome Combined with Sequencing Technology Advances are Moving Us Toward Genomic Medicine




Genomic Medicine is Driving a Strong Global Molecular Diagnostics Market with Estimated Annual Growth of 13.6%

World Market for Molecular Diagnostics, 2009-2015E




Source: 'Valuation of Carried Intangible Assets', Acuity Technology Management, June 2011

Genetics & Oncology Show Highest Growth with Continued Growth in Infectious Diseases in North American Market



Source: 'Valuation of Carried Intangible Assets', Acuity Technology Management, June 2011; The Future Of Molecular Diagnostics: Innovative technologies driving market opportunities in personalized medicine. Business Insights report No: BI00021-012. 23 June 2010.

The Cost of Genome Sequencing Is Decreasing Rapidly and Driving Clinical Adoption of Genomic Analysis




Source: National Human Genome Research Institute


Advances in Sequencing Technology is Driving Adoption of Clinical Genomic Analysis in Molecular Pathology Laboratories

	1 st Genome	Research/ Clinically Relev Clinical Cost & TAT				
	ABI	HiSeq	MiSeq	lon Torrent (Q1 2012)	Ion Proton (Q4 2012)	
Sequencers	Hundreds	One	One	One	One	
Instrument Price	\$ 250,000	\$ 750,000	\$ 125,000+	\$ 75,000	Unknown	
Time	Years	Weeks	27 hours	8 hours	8 hours	
Output	NA	~50 Gb	2 Gb	1 Gb	50 Gb	
Genomic Analysis	Single Genes	Gene Panels, Exome, Genome	Gene Panels	Gene Panels	Gene Panels to Genome	
TIME						
Clinical Genomics is possible today & technology continues to advance						


Genomic Testing by Next Gen Sequencing is Being Used in Molecular Pathology Practice Today



Next Gen Sequencing is the newest Molecular Pathology technology and is being used now Some Molecular Tests Will Move to Next Generation Sequencing While Others Will Remain on Current Platforms



Opportunities Exist for ALL Pathologists to Play Key Roles Within Genomic Medicine



Early Adopters Identify Clinical Grade Databases and Bioinformatics Tools as a High Priority Need

Clinical Database(s):

- Require significant time & money
- Need to define quality & submission standards
- Need to define access & IP issues

• Software Tools for Interpretation and Clinical Usefulness:

- Require significant time & money
- Many software tools being developed
- No interoperability standards
- Will facilitate role for ALL pathologists in Genomic Medicine

Pathologists should be at the table in the development of bioinformatics tools & should learn to use tools as developed

Opportunities Exist for ALL Pathologists to Play Key Roles Within Genomic Medicine



Sequence Data Generation

Sequence Data Interpretation

What is the landscape for ALL Pathologists in the Pre-Analytical & Clinical Consultation Phases for Genomic Testing?

Reporting & Billing

Clinical Consultation

Clinical Decision Support Tools Can Assist *ALL* Pathologists with the Preanalytical and Clinical Consultations for Genomic Medicine

My Cancer Genome	My Cancer Genome	
ARIADNE	Ariadne	
REACTOME	Reactome	
Interactive Biosoftware	Interactive Biosoftware	
INGENUITY s y s t e m s	Ingenuity	
	CollabRx	
🕇 Omicia	Omicia	
 CARTAGENIA	Cartagenia	
	GeneGo	
	Biobase	

Speed of Clinical Adoption Hinges on Several Factors

Decreasing Costs	 Cost of genome analysis is rapidly decreasing Sequencing instruments now are clinically affordable
Increasing Speed	 Can generate sequencing data in 10-36 hours Clinically relevant TAT available today for data generation
Bioinformatics	 Need clinical quality databases and software tools Pathologists must participate in development
Clinical Usefulness	 Genomic Analysis is in clinical use now (small but growing) Research/discovery will increase clinical applications
Payment Uncertainty	 Currently, no specific CPT codes exist for Genomic Analysis Payers do not understand Genomic Analysis
Regulatory Uncertainty	 Federal regulatory uncertainty today Quality standards being led by CAP with AMP & ACMG

Current GA Reporting and Payment Environment is Uncertain

Pre-Analytical

Sequence Data Generation

Sequence Data Interpretation

Reporting & Billing

Clinical Consultation

- No IT standards for reporting in LIS, EHR & PHR
 - Interoperability standards
 - Terminology standards
- Molecular CPT Codes under revision
- No GA CPT Codes available
- Payers do not understand GA
- Early adopters negotiating coverage & reimbursement with each payer for each patient by early adopters

Current GA Regulatory Environment is Uncertain

Pre-Analytical

Sequence Data Generation

Sequence Data Interpretation

Reporting & Billing

Clinical Consultation

- FDA held meeting to understand early clinical users needs & concerns
- No FDA position/guidance
- No CLIA standards for GA
- CAP Next Generation Sequencing (NGS) Work Group
 - NGS Checklist questions
 - \circ PT Exchange

Pathologists Have an Opportunity to Lead the Medical Community in Genomic Medicine

- No single medical specialty is well informed about Genomic Medicine
- Pathologists have an opportunity to be leaders in Genomic Medicine as another diagnostic testing modality
- While genomic technology is rapidly advancing, the discovery process for clinical genomics applications will be an evolution rather than a revolution
- Pathologists can lead in the application of genomic testing as evidence for clinical applications and utility develops

Thoughts on Genomics from a Molecular Pathologist

- Genomics is the next adventure for Molecular Pathology
- Need quality guidelines for data generation and bioinformatics
- Standards hard to develop when everyone still learning ad technology changing so rapidly
- Basic accreditation standards developed for 2012 (CAP, ACMG, AMP) and will evolve as we develop standards/guidelines
- PT is complicated but is coming (CAP)
- Appropriate billing codes needed
- Need to train next generation for genomics

Many Thanks to IOM & CAP Committee Colleagues